New Article on Protecting Intellectual Property & Regulatory Compliance Released

Share Article

Cerulean Associates LLC (http://www.ceruleanllc.com/) is honored to announce the publication of its article on how biotechnology firms, pharmaceutical companies and research and development organizations can protect their intellectual property and achieve regulatory compliance during joint product development and drug discovery collaborations.

Cerulean Associates LLC announces its new article "Protecting Intellectual Property & Regulatory Compliance during Development Collaborations" published in the Winter edition of the European Biopharmaceutical Review.

Drawn upon its author's fifteen years in laboratory, preclinical and R&D environments, as well as his accountability as the CIO and head of an ISO-compliant records management department for a Fortune 50 medical device subsidiary, this article provides six practical steps to improve the retention of intellectual property. Following the recommendations within this article, biopharmaceuticals should be able to enhance the long-term security of their intellectual property. The techniques are adapted from regulatory compliance and information technology, and written to be seamlessly folded into already existent product development processes.

Lucy George, the Deputy Editor of the European Biopharmaceutical Review, said, "We heard about Cerulean's work with companies to build regulatory compliance into products and processes early on, and in review of their literature, saw how they understand and work within the different languages and cultures of compliance, information technology, R&D and legal."

"We approached Cerulean early in the autumn about writing an article for the executives of our readership. The result, written in plain, objective language, is really a "no-nonsense" primer on protecting your intellectual property while maintaining regulatory compliance."

Ms. George further noted, "The article, written by their Managing Director, John Avellanet, is straightforward, clear and full of realistic steps our readership can use today. It is definitely built upon years of experience and learning the hard way."

John Avellanet, the Managing Director of Cerulean, was thankful for the help of Ms. George and her team at Samedan Ltd. (the publisher of the European Biopharmaceutical Review), "Lucy and Neil and the rest of the Samedan team really provided a lot of insight to their audience. Writing down your experiences and knowledge so that it's straightforward and easily adapted by others can be a real challenge in the areas of intellectual property, regulatory compliance and R&D. All the options and advice from Lucy and team really helped shape the final article."

In addition to the published version in the Winter European Biopharmaceutical Review, Cerulean has made a downloadable PDF version of the article available on their website in their resource library.

The European Biopharmaceutical Review provides information for the pan-European biopharmaceutical market across Europe, North America & the rest of the developed world.

The European Biopharmaceutical Review (http://www.samedanltd.com/homepage/ebr.htm) is published quarterly and covers in-depth articles, case studies, meeting and report reviews written by specialists with "hands-on" experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies.

Established in 1997, the European Biopharmaceutical Review is distributed worldwide to more than 15,000 subscribers.

As a recognized leader, Cerulean Associates LLC blends Regulatory Compliance, IT advice and business expertise to bring preclinical R&D and product development organizations faster times to market and better financial results.

Cerulean (http://www.ceruleanllc.com) specializes in helping clients who need sophisticated advice, real results and the personal touch of a small firm. Clients achieve more innovation and a better bottom line. Complete confidentiality is part of every relationship.

Cerulean offers well-rounded, independent insights and help for all areas of IT and Compliance in the life sciences, pharmaceutical, medical device and biotechnology industries, including the contract organizations that support biopharmaceutical companies. Having worked extensively with R&D, IT, Quality and Legal, Cerulean is uniquely qualified to act as objective facilitators and advisors, ensuring mutual understanding and strategic agreement across your organization.

Find out more about Cerulean Associates, its resources, results and advisory services at http://www.ceruleanllc.com/

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

JOHN AVELLANET
Visit website